AA
KROS icon

ALPS Advisors’s Keros Therapeutics KROS Stock Holding History

ALPS Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,673
Closed -$311K – 1038
2025
Q3 		$311K Sell
19,673
-2,276
-10% -$33.6K ﹤0.01% 955
2025
Q2 		$293K Sell
21,949
-7,787
-26% -$105K ﹤0.01% 940
2025
Q1 		$303K Sell
29,736
-3,020
-9% -$35.1K ﹤0.01% 895
2024
Q4 		$519K Buy
32,756
+4,851
+17% +$252K ﹤0.01% 598
2024
Q3 		$1.62M Sell
27,905
-239
-0.8% -$11.8K 0.01% 390
2024
Q2 		$1.29M Buy
28,144
+2,766
+11% +$149K 0.01% 412
2024
Q1 		$1.68M Buy
25,378
+5,766
+29% +$342K 0.01% 380
2023
Q4 		$780K Sell
19,612
-2,281
-10% -$71.5K 0.01% 538
2023
Q3 		$698K Buy
21,893
+149
+0.7% +$5.56K 0.01% 553
2023
Q2 		$874K Buy
21,744
+2,939
+16% +$129K 0.01% 518
2023
Q1 		$803K Buy
18,805
+118
+0.6% +$5.96K 0.01% 512
2022
Q4 		$897K Buy
18,687
+4,665
+33% +$218K 0.01% 503
2022
Q3 		$528K Sell
14,022
-240
-2% -$8.32K 0.01% 580
2022
Q2 		$394K Sell
14,262
-10,409
-42% -$457K ﹤0.01% 655
2022
Q1 		$1.34M Sell
24,671
-2,400
-9% -$123K 0.01% 280
2021
Q4 		$1.58M Sell
27,071
-1,528
-5% -$76.2K 0.02% 314
2021
Q3 		$1.13M Sell
28,599
-2,088
-7% -$74.3K 0.01% 379
2021
Q2 		$1.3M Buy
+30,687
New +$1.66M 0.01% 375

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ALPS Advisors's KROS Position: Q4 2025 in Review

ALPS Advisors sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 19,673 shares — an estimated $311K sold.

ALPS Advisors first reported a position in KROS in Q2 2021 and held it in 18 quarters. The position peaked at $1.68M in Q1 2024. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

  • ALPS Advisors reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
  • ALPS Advisors sold 19,673 Keros Therapeutics shares in Q4 2025, an estimated $311K.
  • ALPS Advisors first reported a position in Keros Therapeutics in Q2 2021 and held it in 18 quarters.
  • ALPS Advisors's Keros Therapeutics position peaked at $1.68M in Q1 2024.
  • 166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on ALPS Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.